Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1996-6-19
|
| pubmed:abstractText |
The significance of circulating antibody to hepatitis C virus (HCV) envelope glycoprotein 2 (E2)/nonstructural protein 1 (NS1) glycoprotein was studied in 83 patients with chronic HCV infection diagnosed by polymerase chain reaction (PCR). E2/NS1 antibody was quantitatively examined by a passive hemagglutination test using recombinant E2/NS1 glycoprotein encompassing amino acids 388 to 664 of the HCV-H strain. The results were correlated with clinical and virological features such as genotypes and viremic levels assessed by a competitive reverse-transcription PCR assay. E2/NS1 antibody was found in 73 patients (88%), and its occurrence was related to viremic levels. E2/NS1 antibody titers were low in asymptomatic HCV carriers with low levels of viral replication; 9 of 17 such patients tested positive for E2/NS1 antibody (53%), compared with 64 of 66 chronic hepatitis C patients (97%) (P < .01). A significant direct relationship was observed between viremic levels and E2/NS1 antibody titers (r = .52, P < .01). Of the 13 patients with low viremic levels of < 10(6) copies/mL, only 5 tested positive for E2/NS1 antibody (38%), whereas 68 of the 70 patients with viremic levels of > or = 10(6) copies/mL had it (97%) (P < .01). As for the relation to HCV genotypes, no difference was seen in E2/NS1 antibody titers among genotypes examined (1b, 2a, and 2b). These findings suggest that the E2/NS1 antibody tested exhibits no neutralizing activity in chronic HCV infection but may serve as a serological indicator of active virus replication.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
947-52
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8621173-Adult,
pubmed-meshheading:8621173-Aged,
pubmed-meshheading:8621173-Base Sequence,
pubmed-meshheading:8621173-Chronic Disease,
pubmed-meshheading:8621173-Female,
pubmed-meshheading:8621173-Genotype,
pubmed-meshheading:8621173-Hemagglutination Tests,
pubmed-meshheading:8621173-Hepacivirus,
pubmed-meshheading:8621173-Hepatitis C,
pubmed-meshheading:8621173-Hepatitis C Antibodies,
pubmed-meshheading:8621173-Humans,
pubmed-meshheading:8621173-Male,
pubmed-meshheading:8621173-Middle Aged,
pubmed-meshheading:8621173-Molecular Sequence Data,
pubmed-meshheading:8621173-Polymerase Chain Reaction,
pubmed-meshheading:8621173-RNA, Viral,
pubmed-meshheading:8621173-Viral Envelope Proteins,
pubmed-meshheading:8621173-Viremia
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection.
|
| pubmed:affiliation |
First Department of Medicine, Osaka University Medical School, Suita, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|